Board of Directors

Mr. Geoffrey M. Glass was elected to the board of directors in July of 2018, and became Chairman in December of 2018. Mr. Glass is President of Clear Sciences, LLC, a management consulting company focused on life sciences industries. Previously he was the CEO, and a board member, of the board of Sancilio Pharmaceuticals, a specialty pharma company. Prior to Sancilio, Mr. Glass served as an executive committee member at Patheon and held a number of senior leadership roles including President of Banner Life Sciences, a business unit of Patheon Pharmaceuticals, Executive Vice President of Sales and Marketing for Patheon Pharmaceuticals, and as Senior Vice President, Strategy, Corporate Development and Integration. Before Patheon, Mr. Glass worked in various executive positions at Valeant Pharmaceuticals (now Bausch Health), including Senior Vice President, Asia Region, Senior Vice President, Chief Information Officer and in both roles was a member of the company’s executive committee. Mr. Glass began his career as a consultant in the life sciences practice for Capgemini Consulting (formerly EY Consulting). He received degrees in Economics and Political Science from the University of Arizona.

Gregory J. Divis was named Chief Executive Ocer in June of 2019, after having served as Chief Operating Ocer (named in March 2018) and Executive Vice President and Chief Commercial Ocer (named in January 2017). Prior to joining Avadel, he served as an Executive in Residence at Linden Capital Partners, a healthcare-focused private equity rm. With over 25 years of experience in the pharmaceutical industry, Mr. Divis served as President and Chief Executive Ocer of Lumara Health, a specialty branded pharmaceutical company focused on women’s health. Prior to Lumara, Mr. Divis held general management, sales, marketing and business development roles at Schering Plough and Sano-Aventis.

Mr. Thornton joined the Board in July of 2017. Mr. Thornton currently serves as Chief Financial Officer of Technopath Clinical Diagnostics, an Irish company that provides quality control materials and software solutions to clinical laboratories, a position he has held since January 2014. Prior to joining Technopath Clinical Diagnostics, from September 2011 to December 2013 Mr. Thornton was Senior Vice President - Business Integration for Alkermes plc, a global biopharmaceuticals company headquartered in Dublin, Ireland; 17 from July 2007 to September 2011 he was Senior Vice President - Corporate and Business Development for Elan Drug Technologies, an Elan Corporation plc division engaged in developing and manufacturing drug delivery technology based pharmaceutical products; from September 2006 to July 2007 he was President and Chief Operating Officer of Circ Pharma Limited, a specialty pharmaceutical company; and from June 2004 to September 2006 he was Chief Financial Officer of Agenus Inc., a NASDAQ-listed biotechnology company. Mr. Thornton worked for the international public accounting firm of KPMG for seven years in Ireland and France and is a fellow of Chartered Accountants Ireland.

Ms. Linda S. Palczuk was elected to the board of directors in July of 2018. She serves as the Chief Operating Officer of Verrica Pharmaceuticals, Inc., a late-stage biopharmaceutical company focused on medical dermatology products, a position she has held since February 2018. Prior to joining Verrica Pharmaceuticals, from July 2017 to February 2018, Ms. Palczuk was President and Chief Executive Officer at Osiris Therapeutics, Inc., a regenerative medicines biotechnology company. Prior to her position at Osiris Therapeutics, Ms. Palczuk had an extensive and successful 30-year career with AstraZeneca Pharmaceuticals and its legacy companies, serving in senior-level commercial and general management roles, including Vice President, Established Brands; Vice President, Global Commercial Excellence; Vice President, Sales & Marketing and Vice President, Sales. Ms. Palczuk received her undergraduate degree in Biology from Franklin and Marshall College and an MBA from the Alfred Lerner College of Business and Economics at the University of Delaware.

Dr. Ende currently serves as President of Ende BioMedical Consulting Group and as a member of Matinas Biopharma’s Board of Directors. Previously he served on the Board of Directors of Genzyme from 2010 until it was acquired by Sanofi-Aventis in 2011 for $20 billion. During his tenure on Genzyme’s Board of Directors, Dr. Ende was a member of the Audit and Risk Management Committees. From 2002 through 2008, Dr. Ende was the senior biotechnology analyst at Merrill Lynch. From 2000 to 2002, Dr. Ende served as the senior biotechnology analyst at Bank of America Securities and, from 1997 to 2000, he served as a biotechnology analyst at Lehman Brothers.

Dr. McCamish joined the Board in December 2019. He is an internationally recognized expert in drug development and manufacturing. Dr. McCamish is currently the President and Chief Executive Officer of Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer. Prior to Forty Seven, Inc., he was the Global Head of Biopharmaceutical Development at Sandoz International, a Novartis company. Dr. McCamish was acknowledged by Novartis with a Chairman award for 2010, 2011, 2012, 2013, 2014, and 2015, and the European Antibody Congress named Dr. McCamish one of the top 50 global antibody industry influencers. Prior to Sandoz, Dr. McCamish served as a member of the executive team of PDL Biopharma, Inc. across several roles, including SVP and Chief Medical Officer. He helped lead the spin out of PDL’s R&D business, which was named Facet Biotech. Due to clinical advances made in both multiple sclerosis with daclizumab and multiple myeloma with elotuzumab, Facet Biotech was acquired by Abbott Labs. Dr. McCamish has also held senior R&D roles at Perlegen Sciences, Amgen, Inc., and Abbott Laboratories. After earning a Ph.D. in Human Nutrition from Penn State and MD from UCLA, he completed his residency and fellowship training at the University of California, Davis (UC Davis). He has also held professorships at UC Davis and Ohio State University.